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A method for human teratogen 
detection by geometrically 
confined cell differentiation and 
migration
Jiangwa Xing1, 2, Yi-Chin Toh1, 3, Shuoyu Xu1, 4 & Hanry Yu1, 2, 4, 5, 6
Unintended exposure to teratogenic compounds can lead to various birth defects; however 
current animal-based testing is limited by time, cost and high inter-species variability. Here, we 
developed a human-relevant in vitro model, which recapitulated two cellular events characteristic of 
embryogenesis, to identify potentially teratogenic compounds. We spatially directed mesoendoderm 
differentiation, epithelial-mesenchymal transition and the ensuing cell migration in micropatterned 
human pluripotent stem cell (hPSC) colonies to collectively form an annular mesoendoderm pattern. 
Teratogens could disrupt the two cellular processes to alter the morphology of the mesoendoderm 
pattern. Image processing and statistical algorithms were developed to quantify and classify the 
compounds’ teratogenic potential. We not only could measure dose-dependent effects but also 
correctly classify species-specific drug (Thalidomide) and false negative drug (D-penicillamine) in the 
conventional mouse embryonic stem cell test. This model offers a scalable screening platform to 
mitigate the risks of teratogen exposures in human.
Teratogens are drugs or chemicals that can interfere with normal embryonic development and induce 
abnormalities in growth and functions1, resulting in various birth defects. Due to the complexity of 
embryonic developmental processes, the identification of teratogens rely mostly on animal models2. 
However, the need to reduce the time and cost associated with animal testing as well as circumvent high 
inter-species variability (~40%) in teratogenic response3 have galvanized the development of alternative 
in vitro models, especially those based on human pluripotent stem cells (hPSCs). The hPSC-based testing 
models developed so far employed temporally-controlled differentiating stem cell cultures using either 
directed differentiation (i.e., differentiation into mesoendodermal4, neural5 or cardiac cells6) or random 
differentiation in embryoid bodies7. Measurements of molecular biomarkers by gene expression4,5,7, flow 
cytometry6, or metabolite detection8,9 were used to determine the teratogenic potential of a compound.
While measuring the temporal expression of molecular biomarkers, such as transcription factors, sur-
face markers or secretory proteins, are fairly successful in predicting drug-induced toxicity on terminally 
differentiated cells10,11, their utility in detecting teratogenic effects of compounds has been limited par-
tially due to the transient, complex and spatially organized nature of molecular signaling events during 
embryonic development. Therefore, a small set of biomarkers cannot adequately describe developmental 
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processes. Embryonic development is characterized by spatio-temporally regulated cell differentiation 
and tissue morphogenesis, which involves collective cell migration12,13. Spatio-temporally regulated dif-
ferentiation and morphogenesis are important in collectively forming developmental structures, such as 
the primitive streak, at the desired time and place during embryonic development13, which are sensitive 
to disruption by teratogens. We hypothesize that constructing a spatial pattern of cell differentiation 
and migration in hPSC cultures can provide a sensitive assay for detecting the teratogenic potential of 
compounds in vitro.
Asymmetries in both mechanical and biochemical environmental cues have been shown to play 
important roles in the spatial patterning of cell differentiation and collective cell migration both in 
vivo13–16 and in vitro17–19. Here, we used the inherent mechanical asymmetry in a micropatterned hPSC 
(μP-hPSC) colony as a simple and robust means to spatially localize the mesoendoderm differentiation of 
hPSCs and allowed them to undergo collective cell migration. Cells at the periphery of the colony pref-
erentially expressed the mesoendoderm marker, BRACHYURY (T) after one day of differentiation. These 
mesoendoderm cells underwent collective cell migration to eventually form a multicellular annular pat-
tern on day 3. In the presence of known teratogens, the formation of the annular mesoendoderm pattern 
was disrupted in a dose-dependent manner. Quantitative analysis of the mesoendoderm morphologic 
features across different compound treatment groups using feature clustering and one-way analysis of 
variance (ANOVA) could successfully distinguish known teratogens from the non-teratogens and avoid 
inter-species variation when compared with the traditional mouse embryonic stem cell test (mEST).
Results
Formation of an annular mesoendoderm pattern by spatially directed differentiation and 
collective cell migration in μP-hPSC colonies. Our goal is to spatially organize cellular events 
(i.e. differentiation and cell migration) characteristic of embryonic development in hPSC cultures to 
assay for drug induced teratogenic effects. We leveraged on asymmetry in the mechanical environment 
imposed by cell micropatterning to drive differential stem cell fates19. We have previously shown that 
differential cell-matrix and cell-cell mediated adhesions between the periphery and interior regions of 
a hPSC colony resulted in their preferential differentiation at the colony periphery20. Therefore, by con-
trolling the geometry of hPSC colony, we can prospectively determine the spatial organization of the 
differentiated cells. Circular micropatterned human pluripotent stem cell (μP-hPSC) colonies were gen-
erated by seeding hPSCs onto circular Matrigel islands of 1 mm in diameter that were patterned with a 
polydimethylsiloxane (PDMS) stencil (Fig.  1a; Supplementary Fig. S1). The surrounding substrate was 
passivated to constrain outgrowth of the μP-hPSC colonies. Cells in μP-hPSC colonies could maintain 
pluripotency and show similar gene and protein expression levels compared to conventionally cultured 
hPSCs cultured in mTeSRTM1 maintenance medium (Supplementary Fig. S2). Immunofluorescence 
staining showed that cells were positive for the pluripotency-associated transcription factors OCT4 and 
NANOG, and surface markers TRA-1–60 and SSEA-4 (Supplementary Fig. S2). Compared with unpat-
terned hPSCs in conventional maintenance culture, the μP-hPSCs showed similar transcript levels of 
both pluripotency-associated and lineage-specific genes (Supplementary Fig. S2).
To induce mesoendoderm differentiation, which is one of the earliest developmental events, the 
μP-hPSC colonies were cultured in a serum-free medium containing Activin A, BMP4 and FGF2 
(Fig. 1a). We monitored the expression patterns of BRACHYURY (T), an early mesoendoderm marker21, 
over three days. T was initially expressed on the periphery of the colony after one day of differentia-
tion (Fig. 1b). By day 3, the T+ cells were displaced inwards by approximately 200 μm from the colony 
edges, and formed a 3D multicellular annular pattern (Fig. 1b). When we patterned hPSCs onto Matrigel 
islands of different geometries but having the same colony area as the 1 mm circular pattern, we found 
that the shape of the T+ mesoendoderm patterns corresponded to the geometries of the underlying 
Matrigel islands and were similarly displaced inwards from the colony periphery (Supplementary Fig. 
S3). However, there was no significant difference in the extent of mesoendoderm differentiation among 
different colony geometries (Supplementary Fig. S3). When we varied the size of the colony while keep-
ing the same circular geometry, we observed that we could still generate an annular mesoendoderm pat-
tern although the proportion of T+ cells in the colony increased (Supplementary Fig. S3). Therefore, we 
demonstrate that stipulating the geometry of the μP-hPSC colonies could reliably control the formation 
of the mesoendoderm pattern.
The consistent displacement of T+ cells from the colony periphery towards the interior from day 1 
to day 3 after mesoendoderm induction suggested that these cells underwent collective cell migration 
(Fig. 1b, Supplementary Fig. S3). To verify this, a 3-day live imaging under 10X objective using phase 
contrast was performed to track the cell movements. Kymograph analysis gave a graphical representa-
tion of spatial position changes along a line over the three days of mesoendoderm induction22. Results 
showed that after one day of induction, periphery cells became motile and migrated out from the main 
colony. While T+ periphery cells in unpatterned hPSC colonies spread out from the colony continuously 
(Supplementary Fig. S4), the physical constraint of the μP-hPSC colonies allowed the periphery cells to 
migrate outwards for only about ~150 μm. The majority of these motile cells then established contact 
with each other, and migrated for about 200 μm towards in the colony interior in an amoeboid manner 
on top of a cell layer in contact with the underlying substrate (Fig.  1c; Supplementary Video 1). The 
spreading and retraction of the motile cells in the μP-hPSC colonies during the 3-day time frame was 
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Figure 1. Formation of annular mesoendoderm pattern in μP-hPSC colony. (a) Schematic depicting 
micropatterning of hPSC colonies and mesoendoderm induction. (b) Phase and immunofluorescence images 
of mesoendoderm marker Brachyury (T) 1–3 days post mesoendoderm induction. Scale bar, 200 μm. (c) 
Montage from a 3-day phase imaging on a quarter section of a circular μP-hPSC colony. Scale bar, 100 μm. 
(d) Kymograph analysis showing the movement of cells along the yellow line shown in (c) throughout the 
3-day live imaging time frame. Scale bar, 50 μm. (e, f) Confocal z-stack sections of T (red) and cell nuclei 
(blue)-labeled multicellular annular structure (e) and its 3-D reconstruction image (f) on day 3. Scale bar, 
30 μm in (f). (g) Immunofluorescence images of mesoendoderm markers EOMES, CRIPTO1 GSC and 
FOXA2. Scale bar, 20 μm. (h,i) Gene expression levels of mesoendoderm markers (h) and EMT markers (g) 
in colony centre and periphery on day 3 relative to undifferentiated hPSCs. Data are average ± s.d. of three 
experiments with duplicate samples. *, p < 0.05 in paired t-test. Insets, phase image showing colony periphery 
and centre.
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manifested as a major migratory front in the kymograph, which was consistently observed in different 
colonies (Fig. 1d).
To study the annular mesoendoderm pattern formed by both differentiation and cell migration, a con-
focal z-stack analysis of the periphery section of a T-labeled μP-hPSC colony was performed to reveal its 
internal structure (Fig. 1e,f). The cross section of the mesoendoderm pattern resembled a ridge-like mul-
ticellular structure (Fig. 1f), where the T+ cells were mainly localized on top of the ridge, and a narrow 
furrow a few microns in width ran underneath the ridge (Fig. 1e). This ridge-like structure appeared to 
resemble an invagination of the epiblast sheet23 seen during primitive streak formation in vivo, which is 
approximately an in vivo equivalent of the hPSCs-derived mesoendoderm cells at the multicellular ridge.
The protein and gene expressions of various mesoendoderm markers and epithelial-mesenchymal 
transition (EMT) markers were examined after three days of mesoendoderm induction to confirm that the 
migrating cells at the colony periphery were indeed mesoendoderm cells (Fig. 1g-i). Immunofluorescence 
staining showed that the mesoendoderm markers EOMES, GSC, CRIPTO, as well as the early definitive 
endoderm marker FOXA2 all co-localized with T at the colony periphery (Fig.  1g). RT-PCR results 
showed that cells at the colony periphery exhibited higher transcript levels of mesoendoderm-specific 
genes (T, MIXL1, GSC, LEFTY2 and FGF8) and lower transcript levels of NANOG compared with cells 
at the colony centre (Fig.  1h). During gastrulation in vivo, epithelial-mesenchymal transition (EMT) 
interrelates mesoendoderm differentiation and subsequent cell migration24. Here, we found that higher 
expression levels of EMT markers (N-cadherin, VIM, TWIST and SNAIL) and lower expression level 
of E-cadherin were also detected at the colony periphery, where the multicellular annular pattern was 
located, as compared to the colony interior (Fig. 1i). These results collectively indicated that the motile 
cells at the colony periphery were mesoendoderm cells.
To demonstrate that the annular multicellular pattern is formed as a result of mesoendoderm cell 
differentiation and migration, we cultured μP-hPSC colonies in a basal differentiation medium without 
adding any mesoendoderm induction factors. Immunostaining results of fixed samples from day 1 to 
3 showed no detectable T expression (Supplementary Fig. S5). Live imaging and kymograph analysis 
indicated that cell migration at the colony periphery was negligible in the absence of mesoendoderm 
induction (Supplementary Fig. S5; Supplementary Video 2). Cells proliferated and distributed relatively 
evenly throughout the whole colony during the 3-day time frame with no annular pattern being formed 
(Supplementary Fig. S5). These data confirmed that the formation of an annular mesoendoderm pattern 
in the μP-hPSC colonies was specifically a result of mesoendoderm cells differentiating and migrating in 
a geometrically confined space.
Sensitivity and specificity of mesoendoderm pattern formation to teratogen treat-
ment. Since the formation of the mesoendoderm pattern encompassed developmentally relevant 
processes (i.e., differentiation and cell migration), we wanted to test if teratogens could disrupt its for-
mation. We treated the μP-hPSC colonies with a paradigm teratogen, Thalidomide (800 μM), and a 
known non-teratogenic compound, Penicillin G (200 μg/ml), at their non-cytotoxic concentrations to 
both hPSCs and human adult fibroblasts (Supplementary Fig. S6). Although T+ cells could be observed 
in both drug-treated colonies after 3 days, the resultant mesoendoderm patterns were distinctively dif-
ferent (Fig. 2a,c). The colonies treated with Penicillin G had a similar annular mesoendoderm pattern to 
the untreated colonies, whereas the colonies treated with Thalidomide showed a much wider mesoen-
doderm pattern that was displaced towards the colony center (Fig. 2a,c). Live imaging and kymograph 
analysis showed that Thalidomide treatment could disrupt the original collective cell migration trajectory 
(Fig. 2d; Supplementary Video 3). While cells in Penicillin G-treated colonies underwent similar migra-
tion trajectory as that in untreated colonies, cells in Thalidomide-treated μP-hPSC colonies migrated 
much more towards the colony center (Fig. 2b,d; Supplementary Video 3 and 4). Since the tested concen-
tration of both compounds was not cytotoxic to the hPSCs, the disruption of the collective cell migration 
process and the final morphology of the mesoendoderm pattern by Thalidomide was likely specific to its 
teratogenic effects. Therefore, our μP-hPSC model could successfully differentiate teratogenic compound 
Thalidomide from non-teratogenic compound Penicillin G.
On the contrary, it was difficult to differentiate the teratogenic effects of Thalidomide and Penicillin 
G by simply measuring the expression levels of molecular biomarkers for mesoendoderm differentiation. 
Cells from Penicillin G (200 μg/ml) and Thalidomide (800 μM) treated colonies as well as untreated 
control colonies were examined for the expression level of three germ layer markers using quantita-
tive RT-PCR (Fig. 2e). There were no significant differences of the expression levels of mesoendoderm 
markers MIXL1 and GSC, mesoderm marker NKX2.5, endoderm marker FOXA2, and ectoderm markers 
PAX6 and NESTIN between the three test groups (Fig.  2e). Both Thalidomide-treated and Penicillin 
G-treated colonies showed a higher expression level of mesoendoderm marker, T, compared to untreated 
control colonies. However, we could not distinguish between Thalidomide and Penicillin G-treated sam-
ples based on T expression levels. Thalidomide-treated samples also exhibited significantly lower expres-
sion level of definitive endoderm marker SOX17 than Penicillin G-treated colonies. However, there was 
no significant difference of SOX17 expression level for either of these two treated samples compared with 
untreated control colonies (Fig. 2e). Therefore, we reasoned that measuring changes in the mesoendo-
derm pattern, which is an assimilation of multiple cellular processes, as an assay readout for teratogenic 
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potential, is sufficiently sensitive and may show better specificity as compared to the expression levels of 
a panel of molecular biomarkers for differentiation.
A quantitative morphometric assay to classify teratogenic potential of compounds. Since 
the morphological features of the annular mesoendoderm pattern in our μP-hPSC model were sensitive 
to teratogen treatment, we wanted to develop a quantitative assay to measure drug-induced morpho-
logical changes to the mesoendoderm pattern. The dose-dependent effect of each compound on the 
mesoendoderm pattern formation was determined by dosing at four test conditions: zero, low, medium 
and high drug concentrations (Fig. 3i). The cytotoxicity of each compound was evaluated in order to find 
the appropriate range of testing concentrations. Since drugs or chemicals may have different cytotoxic 
effects on hPSCs and human adult cells, human embryonic stem cell line, H9 and adult human dermal 
fibroblasts (aHDFs) were tested for cytotoxicity of each drug. The results would represent specific cyto-
toxicity to embryonic and adult cells respectively. Based on the cytotoxicity data, three drug concentra-
tions (designated as low, medium and high) were selected such that the lowest concentration tested was 
not toxic to both H9 cells and aHDFs, and the highest concentration should not be cytotoxic to aHDFs. 
Figure 2. Disruption of annular mesoendoderm pattern by teratogen treatment. (a,c) Phase and T 
fluorescence images of μP-hPSC colonies under Penicillin G (a) and Thalidomide (c) treatment after 3-day 
mesoendoderm induction. Scale bar, 200 μm. (b,d) Kymographs of cell movements around colony periphery 
during 3-day mesoendoderm induction under Penicillin G (b) and Thalidomide (d) treatment. Scale bar, 
50 μm. (e) RT-PCR analysis of expression levels of germ layer markers in untreated, Penicillin G-treated 
and Thalidomide-treated colonies on day 3 relative to undifferentiated hPSCs. Mesoendoderm markers are 
T, MIXL1 and GSC; mesoderm marker is NKX2.5; definitive endoderm markers are FOXA2 and SOX17; 
and ectoderm markers are PAX6 and NESTIN. Data are average ± s.d. of three experiments with duplicate 
samples. *, p < 0.05 in paired t-test.
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The tested concentration was considered as not cytotoxic if it was less than the drug’s 25% inhibitory 
concentration (IC25) to the tested cell line25.
A series of imaging processing and statistical analysis were developed to quantitatively measure the 
teratogenic effects of each drug (Fig.  3). After three days of culture in the mesoendoderm induction 
medium, immunofluorescence images of T were acquired (Fig. 3ii). We employed similar image quantifi-
cation algorithms previously used for analyzing collagen deposition patterns in fibrotic tissues26 to extract 
19 morphological attributes that describe the annular mesoendoderm pattern (Fig. 3iii). After excluding 
four extraneous attributes, which showed random trends, multivariate statistical analysis was applied to 
compress remaining 15 morphological attributes into indices that can indicate for drug-induced changes. 
Here, we used unsupervised hierarchical clustering, which is commonly used in gene microarray anal-
ysis27, to identify groups of morphological attributes that were affected by the drug treatment in similar 
ways, which we termed “morphological clusters”. A dose response plot was then generated for each 
Figure 3. A quantitative morphometric assay for teratogen screening. Workflow for using the μP-hPSC 
model to determine the teratogenic potential of a test compound. Disruption concentration (DC) refers to 
the lowest concentration which morphologically disrupts the mesoendoderm pattern.
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morphologic cluster (Fig. 3iv). One-way analysis of variance (ANOVA) was performed to determine 
whether there were significant morphologic differences among test groups for each drug (Fig.  3v). If 
no significant differences among groups were identified in all morphologic clusters, we could directly 
classify the tested drug as non-teratogenic.
On the contrary, if any morphologic clusters showed significant differences among four test groups, 
post-hoc analysis was then performed in those morphologic clusters to confirm the ANOVA results, as 
well as to find the lowest concentration showing significant mesoendoderm pattern disruption compared 
with the non-treated control group. This concentration was defined as the disruption concentration 
(DC). If DC < IC25,H9, we can infer that the drug is teratogenic, where it affects embryonic development 
without being cytotoxic to embryonic cells25.
Evaluation of the morphometric μP-hPSC model in classifying teratogens. We evaluated the 
drug testing performance of the μP-hPSC model by comparing with a well-established stem cell-based 
assay, the mouse embryonic stem cell test (mEST). The mEST measures whether a drug or chemical can 
disrupt beating cardiomyocyte formation using mouse embryonic stem cells (mESCs), and is currently 
one of the leading in vitro models being validated for teratogenicity screening28,29. Here, five drugs were 
selected according to the United States (US) FDA Pharmaceutical Pregnancy Risk Categories based on 
animal and/or human data (Supplementary Table S1). Four of the drugs are classified as teratogens in 
vivo30–33 (Category D or X) while a non-teratogenic34 drug in vivo (Category B) was included as a neg-
ative control. The mEST can only accurately classify three out of the five selected drugs (Supplementary 
Table 1). Thalidomide affects human but not mouse development and therefore cannot be detected in 
mEST35. D-penicillamine, on the other hand, was misclassified as non-terotogenic in mEST36 due to the 
model’s limitation in assessing only cardiogenesis endpoints37. By choosing these five model drugs, we 
aimed to evaluate whether our μP-hPSC model can potentially show better performance than the mEST.
First, the cytotoxicity data of each drug on both H9 cells and aHDFs were acquired to determine the 
low, medium and high concentrations for different test groups (Supplementary Fig. S6). Drug dosing, 
mesoendoderm induction as well as immunofluorescence images were acquired (Fig. 4a) and processed 
as described above. Seven morphologic clusters were generated by clustering the extracted fifteen mor-
phologic attributes based on their correlations with each other (Fig. 4b). These seven morphologic clus-
ters collectively describe the dispersion (CL1 and CL3), position (CL2 and CL6), area (CL4), kurtosis 
(CL5) and energy (CL7) of the T+ cell distribution within each μP-hPSC colony (Fig. 4c).
The readouts of each morphologic cluster across the four test groups (i.e. control, low, medium, high) 
were plotted for each drug and one-way ANOVA was performed to determine whether there were sig-
nificant differences across the test groups (Supplementary Fig. S7–S11). Post-hoc analysis was performed 
using unpaired t-test and Bonferroni correction methods to verify the ANOVA results and determine the 
DC values of each drug. Our assay based on the morphologic clusters showed that Thalidomide, Retinoic 
acid (RA), D-penicillamine, and Valproic acid (VPA) exhibited significant dose-dependent morphologic 
disruptions of the mesoendoderm pattern (Supplementary Fig. S8–S11). For each drug, at least one 
morphologic cluster showed significant disruption to the mesoendoderm pattern in the low concentra-
tion test groups (Fig. 5a–d). Therefore, the DC values for these four drugs were 30 μM for Thalidomide, 
0.36 ng/ml for RA, 200 μg/ml for D-penicillamine, and 0.1 mM for VPA (Table  1). In the case of the 
negative control drug Penicillin G, ANOVA results showed no significant differences among test groups 
in almost all morphologic clusters except CL6 (p = 0.0122) (Supplementary Fig. S7). The high concen-
tration test group at 1,000 μg/ml showed a significant inward mesoenoderm pattern position toward the 
colony centre compared with zero dose control group (Post-hoc analysis, p = 0.001 < 0.0083) (Fig. 5e, 
Supplementary Fig. 5). Therefore, the DC for Penicillin G was 1,000 μg/ml (Table 1).
Finally we compared the DC values of each drug with their IC25 values to H9 cells to determine 
whether they are teratogenic (Table 1). For Thalidomide, RA, D-penicillamine and VPA, the DC values 
were all less than their corresponding IC25,H9 values, indicating that the disruption of the mesoendoderm 
pattern was likely mediated by alterations to differentiation and migration rather than cytotoxicity effects 
on the embryonic cells. Therefore, they were identified as teratogenic in our model. In contrast, Penicillin 
G had a much higher DC value compared with its IC25,H9 value, and was classified as non-teratogenic. 
Therefore, our quantitative morphometric assay based on the μP-hPSC model could correctly classify the 
five test compounds in accordance to their teratogenicity potential in vivo and showed a better perfor-
mance when compared with the mEST.
Discussion
Human-specific drug screening platforms for teratogenicity are needed to avoid inter-species variations2. 
However, current in vitro hPSC-based models only recapitulated temporal differentiation events4–9, and 
overlooked other key processes during embryonic development, including spatial organization of the 
differentiation and morphogenic processes. Our μP-hPSC model is the first in vitro human developmen-
tal toxicity screening model that recapitulated both spatially controlled differentiation and collective cell 
migration processes during embryogenesis. Here, we demonstrated that this model was sensitive enough 
to distinguish a compound’s teratogenic potential, and exhibited better selectivity to human-specific 
effects than the mEST.
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An important consideration when assessing for teratogenic potential is the dose-dependent response1. 
The effect of a potentially teratogenic compound may not be manifested in vivo due to a low therapeu-
tic dose being used4,38. Therefore, an ideal in vitro screening model should not only identify whether a 
drug is potentially teratogenic, it should also be able to detect its teratogenic effects at clinically-relevant 
concentrations. The drug testing results in this study demonstrated the potential of the μP-hPSC model 
to detect teratogenic effects of compounds at clinically relevant concentrations. In fact, when compared 
with the compound’s highest in vivo concentration (Cmax) in human plasma following therapeutic dos-
ing, the DC values we detected for RA, D-penicillamine and VPA were already lower than or equal to 
their known Cmax values, indicating their strong clinical teratogenic effects (Supplementary Table S2). In 
contrast, the DC value for Penicillin G was much higher than the highest clinical Cmax value reported 
in literature, which was 400 μg/ml39, confirming that it was non-teratogenic (Supplementary Table S2).
Figure 4. Generation of morphologic clusters by unsupervised feature clustering. (a) Phase and T 
immunofluorescence images of μP-hPSC colonies in different drug test groups on day 3. Scale bar, 200 μm. 
(b) Hierarchical clustering of morphologic attributes based on feature correlations. Dash line indicates that 7 
clusters were acquired. (c) Graphical interpretations of the 7 morphologic clusters to describe changes to the 
annular mesoendoderm pattern.
www.nature.com/scientificreports/
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Figure 5. Teratogen screening results in the μP-hPSC model. (a-e) Boxplots of morphologic cluster 
readout, which showed clear dose-dependent disruption effects of each drug among the four test groups. 
The low, medium, high tested concentrations of each drug were 30 μM , 300 μM, 800 μM for Thalidomide 
in (a); 0.00036 μg/ml, 0.0036 μg/ml and 0.036 μg/ml for RA in (b); 200 μg/ml, 400 μg/ml and 800 μg/ml for 
D-penicillamine in (c); 0.1 mM, 0.4 mM, 0.8 mM for VPA in (d); 40 μg/ml, 200 μg/ml, and 1,000 μg/ml for 
Penicillin G in (e). *: p < 0.0083 in post-hoc analysis.
Compound DC IC25H9
Does DC < 
IC25H9?
In the μP-hPSC 
model In vivo human data In mEST
Thalidomide 30 μM >1000 μM Yes Teratogenic Teratogenic30 N.A.
RA 0.36 ng/ml >2000 ng/ml Yes Teratogenic Teratogenic31 Teratogenic
D-penicillamine 200 μg/ml 278 μg/ml Yes Teratogenic Teratogenic32 Non-teratogenic
VPA 0.1 mM 0.13 mM Yes Teratogenic Teratogenic33 Teratogenic
Penicillin G 1000 μg/ml 787 μg/ml No Non-teratogenic Non-teratogenic34 Non-teratogenic
Table 1.  Teratogenicity screening results in the μP-hPSC model-based quantitative morphometric assay.
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One key feature of the μP-PSC model that will facilitate its practical application as a drug-screening 
platform is the consistency at which we could generate the annular mesoendoderm pattern, which pro-
vides a baseline to measure drug-induced effects. In an unpatterned hPSC colony, spatial patterns of 
mesoendoderm differentiation were heterogeneous and vary across cultures (Supplementary Fig. S4). The 
use of geometric confinement by cell micropatterning could induce reproducible spatial patterning of 
mesoendoderm differentiation40. Our μP-hPSC model not only recapitulated spatially induced mesoen-
doderm differentiation, but also self-organized collective cell migration within the colony, forming repro-
ducible mesoendoderm patterns. We have shown that such annular mesoendoderm pattern could be 
generated with different hPSC lines (Supplementary Fig. S12). Compared with other methods of creating 
environmental gradient to pattern stem cell fates, such as microfluidic patterning of soluble factors41,42 
or micropatterned feeder cells43 or hydrogels44, the μP-hPSC approach is straightforward to implement, 
readily scalable, and is more amenable to high content imaging for downstream data collection and anal-
ysis. The scalability and robustness of the μP-hPSC model will facilitate future systematic validation with 
a large number of test compounds, and the establishment of an animal-alternative screening platform to 
detect the teratogenicity potential of chemical compounds in human.
Methods
Cell maintenance and differentiation. All the three hPSC lines, which includes human embryonic 
cell lines H9 and H1, and human induced pluripotent stem cell IMR90 were obtained from WiCell 
Research Institute, Inc. (Madison, WI, USA) and followed the same maintenance and differentiation 
protocols. Cells were cultured in hPSC-qualified MatrigelTM (354277, BD Biosciences) coated cell culture 
plates using mTeSRTM1 medium (05850, StemCellTM Technologies). Mechanical scraping was applied 
during normal passaging in order to only get undifferentiated hPSC colonies after Dispase (07923, 
StemCellTM Technologies) treatment. To induce mesoendodermal differentiation, cells were cultured 
in basal STEMdiffTM APELTM medium (05210, StemCellTM Technologies) supplemented with 100 ng/
ml Activin A (338-AC-025, R&D Systems), 25 ng/ml BMP4 (314–BP–010, R&D Systems) and 10 ng/ml 
FGF2 (233–FB–025, R&D Systems).
The adult human dermal fibroblast (aHDF) was obtained from Lonza (Singapore) and cultured in 
DMEM high glucose medium (10569–010, Gibco) supplemented with 10% FBS (SV30160.03, Thermo 
Scientific Hyclone) and 1% Pen-Strep (09367-34, Nacalai Tesque). To get single cell suspension for cell 
seeding, the cells were washed with 1X PBS three times and treated with 0.25% Trypsion-EDTA (25200-
114, Gibco) at 37 °C for 3–4 min.
Fabrication of PDMS stencils for micropatterning. The polydimethylsiloxane (PDMS) sten-
cil composed of a PDMS gasket and a thin PDMS sheet with cut micropatterns, both of which were 
designed with L-edit Pro software (Tanner, USA). The micropatterns used in this study include circles, 
squares, rectangles and semi-circular arcs with areas of 7.85 × 105 μm2 and 1.96 × 105 μm2. For teratogen 
screening, only circles with area of 7.85 × 105 μm2 were used, which corresponds to 1 mm in diameter. 
A laser-cutter (Epilog Helix 24 Laser System, USA) was used to cut the designed patterns on a 127 μm 
thick PDMS sheet (Specialty Silicone Products Inc.), then the PDMS sheet was bonded to a laser-cut, 
2mm thick PDMS gasket using liquid PDMS and baked at 60 °C for 3–4 hr to finally get the PDMS stencil 
for micropatterning (Supplementary Fig. S1). The stencils were sterilized by autoclaving at 120 °C for 
30 min every time before use.
Generation of μP-hPSC colonies and live imaging microscopy. The autoclaved PDMS stencil 
was first sealed onto a 60 mm petri dish (Nunc) using 200 μl of 70% ethanol. After drying in the cell 
culture hood, 450 μl MatrigelTM in DMEM/F12 (11330032, GIBCO) was then added into each sten-
cil and incubated for 5 hr at 37 °C before use. To obtain single cell suspension, the hPSC culture was 
treated with Accutase (SCR005, Merck Millipore) for about 10 min, and the cells were resuspended in 
mTeSR1 medium supplemented with 10 μM Y27632 (688000, Calbiochem, Merck Millipore). The cells 
were seeded onto the PDMS stencils at 100% confluence density of 4444 cells/mm2 and allowed to attach 
for 1 hr. The stencil was then removed and the unpatterned substrate was passivated by backfilling with 
0.5% Pluronic F-127 (P2443–1KG, Sigma-Aldrich) in DMEM/F12. After 10 min incubation, the μP-hPSC 
colonies were washed 3 times with DMEM/F12 and incubated at least for 3 hr in mTeSRTM1 medium sup-
plemented with 10 μM Y27632 before changed to mTeSRTM1 medium alone. Differentiation was initiated 
24 hr post seeding and lasted for 3 days before collecting the samples. For phase contrast live imaging, 
images were acquired every 20 min by BioStation CT (Nikon) using 10X objective. The imaging period 
started since the induction of differentiation and lasted for 3 days.
Immunofluorescence staining and fluorescence microscopy. Samples were fixed for 20 min in 
3.7% paraformaldehyde, and permeabilized for 15 min with 0.5% Triton X-100 in PBS. After 3 hr incu-
bation at room temperature (RT) in blocking buffer (2% BSA and 0.1% Triton X-100 in PBS), they were 
incubated overnight at 4 °C with primary antibodies (5-10 μg/ml in blocking buffer). The primary anti-
bodies used in this study were rabbit anti-Nanog (ab21624, Abcam), goat anti-Oct4 (ab27985, Abcam), 
mouse anti-TRA-1-60 (MAB4360, Millipore), mouse anti-SSEA4 (90231, Millipore), goat anti-Brachyury 
(AF2085, R&D Systems), rabbit anti-Eomes (ab23345, Abcam), rabbit anti-Cripto1 (ab19917, Abcam), 
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rabbit anti-FoxA2 (ab40874, Abcam), and goat anti-GSC (sc-22234, Santa Cruz Biotechnology). The 
samples were washed 4 times with 15 min interval before adding secondary antibodies. The second-
ary antibodies used in this study were donkey anti-rabbit IgG-Alexa Fluor® 488 (1:1000, A21206, 
Life Technologies), donkey anti-goat IgG-Alexa Fluor® 546 (1:1000, A11056, Life Technologies), goat 
anti-mouse IgM-FITC (1:500, sc-2082, Santa Cruz), goat anti-mouse IgG-FITC (1:500, sc-2010, Santa 
Cruz), and goat anti-rabbit IgG-Alexa Fluor® 555 (1:1000, A21429, Life Technologies). After 1 hr incu-
bation with the secondary antibodies at RT, samples were washed for 4 times with 15 min interval and 
counter-stained with 10 μg/ml Hoechst 33342 (H3570, Invitrogen) for 5 min. After that, samples were 
washed 3 times with PBS and then mounted using Fluorsave (345789, Calbiochem, Merck Millipore). 
Confocal images were acquired using Zeiss LSM 5 DUO microscope (Zeiss), and immunofluorescence 
images of entire μP-hPSC colonies for quantitative analysis were acquired using Olympus IX81 epifluo-
rescence microscope (Olympus, Japan) with a motorized stage (Prior Scientific).
Drug preparation. The drugs tested in this study were Penicillin G (P3032–10MU, Sigma-Aldrich), 
Thalidomide (T144–100MG, Sigma-Aldrich), RA (554720-500MGCN, Merck, Millipore), D-penicillamine 
(P4875-5G, Sigma-Aldrich) and VPA (P4543-10G, Sigma-Aldrich). The stocks of Thalidomide and RA 
were dissolved in DMSO (D2650, Sigma-Aldrich), while others are dissolved in distilled water. The dilu-
tions of Thalidomide and RA for drug treatment in our μP-hPSC model were prepared such that DMSO 
concentration was less than 0.25%.
Cytotoxicity assay. The cytotoxicity test was done in 96-well tissue culture plates with 100 μl of 
medium with or without the drug. For each drug, 8 concentrations with 5-fold dilution were tested 
together with the vehicle controls. For H9 cells, the plates were coated with MatrigelTM before cell seed-
ing. 10,000 hES cells or 1,000 aHDF cells were plated into each well and cultured for 3 days in the test 
solution with half change of the medium with or without the drug every day. On day 3, cell viability was 
measured using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, G3580, Promega). 
Three independent tests were done for each drug to finally acquire the cytotoxicity results. IC25 values 
were acquired from either logistic regression using OriginPro 9 or direct reading from the cytotoxicity 
curve.
RNA isolation, cDNA synthesis and quantitative RT-PCR. Total RNA was extracted from the 
samples on day 3 of the differentiation using the RNeasy® Plus Micro Kit (74034, QIAGEN) according 
to manufacturer’s protocol. Then cDNA was synthesized from the extracted RNA using High Capacity 
RNA-to-cDNA Kit (4387406, Applied Biosystems, Life Technologies). To analyze the gene expression 
levels of each sample, quantitative RT-PCR was performed using FastStart Universal SYBR Green Master 
(ROX) (04913914001, Roche) on the ABI 7500 Fast Real-Time PCR system (Applied Biosystems, Life 
Technologies) according to the manufacturer’s standard protocol. The relative quantitative expressions 
values of target genes were normalized to GAPDH and expressed relative to the levels of undifferen-
tiated hPSCs using the Δ Δ CT method. All primers used were commercially validated primers from 
GeneCopoeiaTM except for MIXL1, GSC, E-cadherin, N-cadherin, VIM, TWIST and SNAIL. The primer 
sequences/Catalogue numbers can be found in Supplementary Information (Supplementary Table S3).
Image analysis. Kymograph analysis. Kymographs were generated using ImageJ (Version 1.46r, 
NIH) with installed MultipleKymograph plugin. After importing the time series of μP-hPSC colony 
images, an average intensity Z-projection image was generated. A segmented line was drawn at the region 
of interest (ROI) (which was the colony periphery in our study) in the Z-projection image and then 
restored in the original time series image window using Restore Selection Tool. After that, a kymograph 
could be generated with a line width of 1 using MultipleKymograph Plugin, which shows the movement 
of cells along the segmented line within time of interest.
Morphological feature extraction. Morphological feature extraction from T fluorescence images was 
done in MATLAB Image Processing Toolbox (Mathworks). First, the outline of the μP-hPSC colony was 
identified by intensity difference compared with background and its centroid position was determined. 
The Otsu’s method was then applied to segment the whole μP-hPSC colony into T+ region and T- region. 
The relative positions/distributions of each region were acquired. All of the 19 morphological features 
were extracted based on the distribution of the T+ region, mainly including the area of the T+ region, 
relative distance of the T+ region to the colony centroid and outline, the standard deviation, coefficient 
of variance, skewness, kurtosis, entropy and energy of the distribution of the T+ region, etc.
Unsupervised Feature clustering. The feature clustering was done in R (Version 3.1.2). After excluding 
four extraneous features, which showed random trends, the remaining 15 features were clustered into 
seven morphologic clusters based on their feature correlations by hierarchical clustering using complete 
linkage method. Based on the clustering result, the feature average values for each morphologic cluster 
were calculated and plotted in boxplots.
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Statistical analysis. One-way ANOVAs were used to access the effects of test compounds on the 
morphologic changes of mesoendoderm patterns in R. Post-hoc analysis was performed to verify sig-
nificant ANOVA results and determine DC values of each drug using unpaired t-test and Bonferroni 
correction methods. Since there were four test groups for each compound screening, six comparisons 
using unpaired t-test were generated. According to Bonferroni correction, the adjusted critical p value for 
0.05 significance would be 0.05 divided by the total number of comparisons, which was 0.0083 (0.05/6). 
Therefore, the acquired p values by unpaired t-tests were compared with the adjusted critical p value 
0.0083.
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